Trial Profile
A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Neovascular glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms VEGA
- Sponsors Bayer
- 16 Dec 2020 Primary endpoint (Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1) has not been met, as per results published in the Advances in Therapy
- 16 Dec 2020 Results published in the Advances in Therapy
- 27 Mar 2020 According to a Bayer media release, the company announced that Bayer Yakuhin has received approval for the additional indication of neovascular glaucoma for the intravitreal VEGF inhibitor EYLEAsolution for intravitreal injection 40 mg/mL. This approval is based on the data from two Phase III studies (VEGA and VENERA).